This study developed and validated a novel TCM-derived gene signature that reliably stratifies breast cancer patients into distinct risk groups and is independently prognostic. While its clinical utility requires extensive validation in prospective studies before it can inform patient management, this novel gene signature may serve as a potential tool for individualized risk assessment and prognosis prediction, while also generating compelling hypotheses for guiding immunotherapy and targeted therapy strategies, contributing to the ongoing exploration of precision oncology in breast cancer.
Qiu et al. (Thu,) studied this question.